Skip to main content
main-content

05-06-2021 | ASCO 2021 | Conference coverage | Video

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC

share
SHARE

Stephen Liu talks through the latest findings from the ARROW trial of pralsetinib for patients with RET fusion-positive advanced non-small-cell lung cancer (3:18).

Read transcript

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.